The growth of the global HIV drugs market is attributed to increase in number of patients suffering from HIV/AIDS.

PORTLAND, OREGON, UNITED STATES, September 7, 2022 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, “Global HIV Drugs Market by Medication Class and Region: Global Opportunity Analysis and Industry Forecast, 2020–2027,"

The global HIV drugs market accounted for $30.89 billion in 2019, and is expected to reach $36.49 billion by 2027, registering a CAGR of 3.8% from 2020 to 2027. Human immunodeficiency virus (HIV) is one of the most challenging infectious diseases that affected around 39.6 million people globally by the end of 2018, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). Antiretroviral Therapy (ART) drugs are used for the treatment of HIV as they prevent the growth of the HIV virus.

Download Free Sample Copy of The Report:
https://www.alliedmarketresearch.com/request-sample/1867

The North America and Europe markets hold larger share in the HIV drugs market due to the rising cases of HIV-infected people and the presence of top pharmaceutical companies in these regions. Moreover, the well-established healthcare systems in these regions leading to higher diagnosis & treatment rate is one of the major reasons for the higher share of North America and Europe in the global HIV drugs market.

Major Key Players -

Key players in this market have adopted new product launch as the preferred strategy to expand their business. The key players profiled in this report include Boehringer Ingelheim International GmbH, Merck & Co., Inc., GalaxoSmithKline plc. AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, and Cipla Limited.

Table of Content:

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments

1.2.1.List of key players profiled in the report

1.3.Research methodology

1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 5:HIV DRUGS MARKET, BY REGION

5.1.Overview
Market size and forecast

5.2.North America

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by country

5.3.Europe

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by country

5.4.Asia-Pacific

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by country

For Purchase Enquiry at:
https://www.alliedmarketresearch.com/purchase-enquiry/1867

On the basis of region, the overall market in North America is expected to account for nearly half of the total market share in 2019 and maintain this dominance through 2027. From 2020 to 2027. The other two regions analyzed in the report are LAMEA and Europe.

FREQUENTLY ASKED QUESTIONS?

Q1. What is the total market value of HIV drugs market report ?
Q2. What would be forecast period in the market report?
Q3. What is the market value of HIV drugs market in 2027?
Q4. Which is base year calculated in the HIV drugs market report?
Q5. Which are the top companies hold the market share in HIV drugs market?
Q6. Which is the most influencing segment growing in the HIV drugs market report?

Key findings of the study -

North America accounted for 48.40% market share in 2019, and is expected to maintain this trend over the forecast period.
On the basis of medication class, the multi-class combination drugs segment is anticipated to grow at a CAGR of 4.1% from 2020 to 2027.
The Asia-Pacific HIV drugs market is estimated to grow at a CAGR of 4.4% during the forecast period.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.